Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

One Week of Magnesium Supplementation Lowers IL-6, Perceived Pain and Increases Post Exercise Blood Glucose in Response to Downhill Running

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04216836
Recruitment Status : Completed
First Posted : January 3, 2020
Last Update Posted : January 3, 2020
Sponsor:
Collaborators:
Beijing Sport Uninversity
Coventry University
Information provided by (Responsible Party):
Charles Steward, University of Worcester

Brief Summary:
This study investigated the effect of magnesium supplementation on exercise performance and functional recovery in recreational endurance athletes in conjunction with measures of blood glucose, lactate, IL-6 and sIL-6R.

Condition or disease Intervention/treatment Phase
Magnesium Deficiency Dietary Supplement: Magnesium oxide Dietary Supplement: Placebo Not Applicable

Detailed Description:
Magnesium status can directly affect circulating glucose concentrations both during and post exercise. In addition, magnesium supplementation has been shown to reduce circulating IL-6 concentrations post exercise in humans. It is conceivable that such observations are linked through the role of IL-6 in glucose regulation, possibly in combination with sIL-6R. Together, magnesium intake may have the potential to effect exercise performance and recovery through glucose availability. This in turn may be connected to the production of IL-6 and sIL-6R which have been established to influence exercise fatigue and perception of pain (muscle soreness).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: One Week of Magnesium Supplementation Lowers IL-6, Perceived Pain and Increases Post Exercise Blood Glucose in Response to Downhill Running
Actual Study Start Date : June 28, 2018
Actual Primary Completion Date : March 1, 2019
Actual Study Completion Date : March 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: High magnesium diet (SUP condition)
Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of magnesium oxide. This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
Dietary Supplement: Magnesium oxide
Magnesium capsule

Experimental: Low magnesium diet (CON condition)
Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
Dietary Supplement: Placebo
Cornflour capsule manufactured to mimic the 166.6 mg magnesium capsule.




Primary Outcome Measures :
  1. Downhill 10 km treadmill time trial performance [ Time Frame: 1 day ]
    Maximal 10 km time trial performance on a treadmill

  2. 24 hr post exercise maximal force testing of the dominant leg on the isokinetic dynamometer [ Time Frame: 1 day ]
    Maximal force produced from the dominant leg (eccentric and concentric) on an isokinetic dynamometer.


Secondary Outcome Measures :
  1. Glucose [ Time Frame: up to 2 days ]
    Capillary blood samples at rest, during, immediately post, 1 hr post and 24 hrs post 10 km downhill time-trial. A Biosen analyser was used to analyse glucose concentrations.

  2. Interleukin-6 [ Time Frame: up to 2 days ]
    Venous blood samples at rest, immediately post, 1hr post and 24 hrs 10 km downhill time trial. Enzyme-linked immunosorbent assays were used to analyse interleukin-6.

  3. Soluble interleukin-6 receptor [ Time Frame: up to 2 days ]
    Venous blood samples at rest, immediately post, 1hr post and 24 hrs 10 km downhill time trial. Enzyme-linked immunosorbent assays were used to analyse soluble interleukin-6.

  4. Perceived muscle soreness [ Time Frame: up to 4 days ]
    A 10cm visual analogue scale was used to assess perceived muscle soreness, the scale started at 0 (no pain) and finished at 10 (unbearable pain)

  5. Lactate [ Time Frame: up to 2 days ]
    Capillary blood samples at rest, during, immediately post, 1 hr post and 24 hrs post 10 km downhill time-trial. A Biosen analyser was used to analyse lactate concentrations.

  6. Creatine kinase [ Time Frame: up to 2 days ]
    Venous blood samples at rest, immediately post, 1hr post and 24 hrs 10 km downhill time trial. A Reflotron analyser was used to analyse creatine kinase concentrations.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Regular recreational runner, running around 3 times per week
  • Capable of running 10 km in ~ 40 minutes.

Exclusion Criteria:

  • Any signs or symptoms of cardiovascular issues.
  • Any recent form of injury or illness.
  • Currently, or in the last 3 months, have consumed multivitamin supplements
  • Currently, or in the last 3 months, have consumed anti-inflammatory medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04216836


Locations
Layout table for location information
United Kingdom
University of Worcester
Worcester, Worcestershire, United Kingdom, WR1 3AS
Sponsors and Collaborators
University of Worcester
Beijing Sport Uninversity
Coventry University
Publications:

Layout table for additonal information
Responsible Party: Charles Steward, Lecturer, University of Worcester
ClinicalTrials.gov Identifier: NCT04216836    
Other Study ID Numbers: SH17180029-R
First Posted: January 3, 2020    Key Record Dates
Last Update Posted: January 3, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Charles Steward, University of Worcester:
Magnesium
Supplementation
Interleukin-6
Soluble interleukin-6 receptor
Glucose
Pain
Exercise performance
Exercise recovery
Downhill running
Additional relevant MeSH terms:
Layout table for MeSH terms
Magnesium Deficiency
Deficiency Diseases
Malnutrition
Nutrition Disorders
Magnesium Oxide
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents